SCHEMBL2056812

SCHEMBL2056812

Nc1nc(Nc2ccc(N3CCC(N4CCCC4)CC3)c(F)c2)nn1-c1cc(-c2cccc(F)c2)c2c(n1)C1CCN2CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 11/20 0.63
KDR P35968 4/20 0.44
INSR P06213 1/20 0.44
KIT P10721 3/20 0.43
FLT3 P36888 3/20 0.43
MET P08581 2/20 0.43
SRC P12931 2/20 0.43
EGFR P00533 2/20 0.43
AURKA O14965 1/20 0.43
RET P07949 1/20 0.43
PDGFRA P16234 1/20 0.43
TYRO3 Q06418 1/20 0.43
DDR1 Q08345 1/20 0.43
MERTK Q12866 1/20 0.43
AURKB Q96GD4 1/20 0.43
ALK Q9UM73 1/20 0.43
CSF1R P07333 1/20 0.38
CDK4 P11802 1/20 0.38
CDK6 Q00534 1/20 0.38
ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1329581 0.94 AXL (0.70) AXLKDRINSRKITFLT3
SCHEMBL30090688 0.94 AXL (0.70) AXLKDRINSRKITFLT3
SCHEMBL2056590 0.92 AXL (0.61) AXLKDRINSRKITFLT3
SCHEMBL2056767 0.92 AXL (0.60) AXLKDRINSRKITFLT3
SCHEMBL2056631 0.91 AXL (0.59) AXLKDRINSRKITFLT3
SCHEMBL1330529 0.91 AXL (0.62) AXLKDRINSRKITFLT3
SCHEMBL1331016 0.90 AXL (0.60) AXLKDRINSRKITFLT3
SCHEMBL30090699 0.90 AXL (0.60) AXLKDRINSRKITFLT3
SCHEMBL1329742 0.88 AXL (0.58) AXLKDRINSRKITFLT3
SCHEMBL1331298 0.88 AXL (0.58) AXLKDRINSRKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140128400-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2014-05-08 US claimed
US-20130018051-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2013-01-17 US claimed
EP-2328888-B1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2012-11-07 EP claimed
US-20110105512-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-05-05 US claimed
US-9206161-B2 Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-20150126514-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS MIDCAP FINANCIAL TRUST 2015-05-07 US disclosed
US-8933080-B2 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-01-13 US disclosed
US-20140128400-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2014-05-08 US disclosed
US-8658669-B2 Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2014-02-25 US disclosed
US-8431594-B2 Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-04-30 US disclosed
US-20130018051-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2013-01-17 US disclosed
EP-2328888-B1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2012-11-07 EP disclosed
US-20110105512-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105512-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS ERBB2, AXL, ERBB3 AXL 2/4885KDR 98/4885INSR 301/4885
US-20140128400-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, ERBB2, TYRO3 AXL 1/4885KDR 69/4885INSR 304/4885
US-20150126514-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, ERBB2, TYRO3 AXL 1/4885KDR 69/4885INSR 304/4885
US-20130018051-A1 BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, ERBB2, TYRO3 AXL 1/4885KDR 69/4885INSR 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.